Founded in Menlo Park, California, KORTUC is dedicated to enhancing the effectiveness of cancer treatments through its innovative radio-sensitizing platform. The company's core mission is to provide more effective options for cancer radiotherapy by addressing tumor hypoxia. KORTUC offers a unique radiosensitizer primarily composed of hydrogen peroxide (H2O2), which, when injected into tumors, eliminates hypoxia and increases tumor sensitivity to radiation therapy. This approach aims to maximize the safety and efficacy of radiotherapy and immunotherapy for cancer patients.
KORTUC has garnered attention for its groundbreaking approach to cancer treatment, attracting notable investors and partnerships within the medical and biotech communities. The company has achieved significant milestones in clinical trials, demonstrating the potential of its radiosensitizer to improve patient outcomes. By enhancing the power of radiotherapy, KORTUC is making a substantial impact on the field of oncology, offering new hope for more effective cancer treatments.
